HepaLife Logo - Click to return to home pageBanner Graphic
Phone us on 800 518 4879
Click here to search HepaLife 
 arrowHome | Our Company | Our Portfolio | Investor Relations | Contact                    Text Size: S M L  |  Symbol: HPLF
Press Releases and Investor Alerts

Corporate Overview

BulletBioartificial Liver Device  BulletIn-Vitro Toxicology Testing   BulletInstitutional Funding


Based in Boston, Massachusetts, HepaLife Technologies Inc., (Symbol: HPLF), together with its wholly owned subsidiaries, is a biotechnology company developing proprietary cell-based medical technologies to improve, protect and save lives, addressing prevalent human health concerns.

Working with unique and patented cell-based technologies, our scientists and research partners strive to improve the quality of life for those with liver disease, help make drugs safer by developing better toxicity testing, and aim to ward off pandemic flu with a vaccine production method that is faster and more flexible than today's antiquated systems.

Title Bullet Bioartificial liver device

Each year, an estimated two million people die of liver disease. Acute liver failure is associated with mortality of up to 90%, with currently limited or no treatment option. Today, with our proprietary technology, a bioartificial liver is closer to reality than ever.

Our technology includes an extracorporeal bioartificial liver device for the treatment of liver failure, incorporating:

  • the PICM-19 patented embryonic porcine liver stem cell line
  • a high performance bioreactor
  • the advanced HepaDrive™ perfusion system

Bullet Arrow more...

Liver Disease
Liver Cirrhosis

Title Bullet In-Vitro toxicology and pre-clinical drug testing platforms

Prescription drug side effects account for 200,000 deaths each year, and drug toxicity is the single most common reason for the FDA to deny approval or withdraw a drug from market. Our technology is the basis for much-needed novel drug toxicity testing.

Our technology utilizes the patented PICM-19 embryonic porcine liver stem cell line, displaying enhanced liver-specific metabolic functions for determining toxicity of new pharmacological compounds while in the early development process.

Bullet Arrowmore...

Porcine Hepatocyte
Porcine Liver Stem Cell

Title Bullet Institutional Funding

Because of the importance of our products in development, we have obtained sufficient institutional financing to further our goals.

 

Send this page to a friendSend Page to a Friend      Investor Alerts

Home  |  Our Company  |  Our Portfolio  |  Investor Relations  |  Contact  |  Disclaimer   
© Copyright 2008 HepaLife Technologies    All Rights Reserved.